Search

Bristol-Myers Squibb Co.

Closed

SectorHealthcare

63.82 -1.25

Overview

Share price change

24h

Current

Min

63.82

Max

64.28

Key metrics

By Trading Economics

Income

638M

3.3B

Sales

1.5B

13B

P/E

Sector Avg

14.011

57.002

EPS

2.04

Dividend yield

3.87

Profit margin

25.561

Employees

32,500

EBITDA

1.3B

4.9B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+3.87% upside

Dividends

By Acuity

Dividend yield

Sector Avg

3.87%

2.22%

Next Earnings

29 paź 2026

Next Ex Dividend date

2 paź 2026

Market Stats

By TradingEconomics

Market Cap

2.2B

130B

Previous open

65.07

Previous close

63.82

News Sentiment

By Acuity

43%

57%

129 / 340 Ranking in Healthcare

Bristol-Myers Squibb Co. Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 sie 2026, 20:06 UTC

Social Media
News
Event

Bristol-Myers Squibb shares are lower after FDA approval of Zenbexus due to concerns over its $29,500 pricing, which may dampen market sentiment.

13 sie 2026, 23:56 UTC

News
Event

Bristol-Myers Squibb's shares are lower after FDA approval of ZENBEXUS for multiple myeloma, amid concerns over drug risks and ongoing trial verification.

12 sie 2026, 23:56 UTC

Bristol-Myers Squibb Co shares rose in after-market trading following U.S. Consumer Price Index data, easing concerns about aggressive Federal Reserve interest rate hikes.

11 sie 2026, 23:01 UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, rising from earlier gains and positioned above their 20-day moving average.

10 sie 2026, 23:51 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours. The decline follows three consecutive sessions of gains amid shifting labor market sentiment.

8 sie 2026, 00:01 UTC

Bristol-Myers Squibb Co. shares are lower in after-market trading, continuing a decline since Friday's close despite being above the 20-day moving average.

7 sie 2026, 23:06 UTC

Bristol-Myers Squibb shares lower in after-market trading, despite maintaining a position above the 20-day moving average. No specific news was identified.

6 sie 2026, 23:26 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, influenced by broader market trends and a stronger U.S. Dollar amid rising jobless claims.

5 sie 2026, 23:01 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours. No specific news was identified to explain the movement.

4 sie 2026, 23:16 UTC

Bristol-Myers Squibb Co. shares gained in after-market trading, reflecting a modest uptick of 0.20% and remaining above their 20-day moving average.

3 sie 2026, 23:02 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, with no specific news identified to explain the movement. The stock remains above its 20-day moving average.

31 lip 2026, 19:16 UTC

News
Social Media

Bristol-Myers Squibb shares rise as multiple analysts raise price targets following strong second-quarter results and an upward revision of annual guidance.

30 lip 2026, 22:51 UTC

Bristol-Myers Squibb Co. shares are lower in after-market trading, reversing earlier gains and reflecting a notable retreat from earlier highs.

29 lip 2026, 23:36 UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, amid rising interest rates and inflation concerns contributing to market volatility. No specific news was identified.

28 lip 2026, 20:06 UTC

News

Bristol-Myers Squibb is rising as it enhances collaboration with Nvidia for AI in drug discovery, improving efficiency in development processes.

27 lip 2026, 22:01 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, with no specific news driving the decline amid mixed broader market performance.

24 lip 2026, 17:56 UTC

Bristol-Myers Squibb Co shares are higher, maintaining a positive trajectory since Thursday's close. No specific news was identified to explain today's price action.

23 lip 2026, 00:01 UTC

Bristol-Myers Squibb Co shares are modestly higher in after-market trading, recovering from an earlier dip and remaining above their 20-day moving average.

22 lip 2026, 23:11 UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, reaching a notable rise while remaining above the 20-day moving average.

21 lip 2026, 23:36 UTC

Bristol-Myers Squibb Co. shares are near unchanged in after-market trading, remaining above their 20-day moving average amid a solid performance backdrop.

20 lip 2026, 23:41 UTC

Bristol-Myers Squibb Co. shares are trading roughly flat in after-market hours, remaining effectively unchanged since Monday's close amid no specific news.

Peer Comparison

Price change

Bristol-Myers Squibb Co. Forecast

Price Target

By TipRanks

3.87% upside

12 Months Forecast

Average 66.3 USD  3.87%

High 80 USD

Low 40 USD

Based on 21 Wall Street analysts offering 12 month price targets forBristol-Myers Squibb Co. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

21 ratings

9

Buy

11

Hold

1

Sell

Sentiment

By Acuity

129 / 340 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
help-icon Live chat